RS65414B1 - Peptidni analog acilovanog oksintomodulina - Google Patents
Peptidni analog acilovanog oksintomodulinaInfo
- Publication number
- RS65414B1 RS65414B1 RS20240329A RSP20240329A RS65414B1 RS 65414 B1 RS65414 B1 RS 65414B1 RS 20240329 A RS20240329 A RS 20240329A RS P20240329 A RSP20240329 A RS P20240329A RS 65414 B1 RS65414 B1 RS 65414B1
- Authority
- RS
- Serbia
- Prior art keywords
- peptide analog
- oxyntomodulin peptide
- acylated oxyntomodulin
- acylated
- analog
- Prior art date
Links
- PXZWGQLGAKCNKD-DPNMSELWSA-N molport-023-276-326 Chemical class C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 PXZWGQLGAKCNKD-DPNMSELWSA-N 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20170103798 | 2017-08-16 | ||
| PCT/KR2018/009425 WO2019035672A1 (ko) | 2017-08-16 | 2018-08-16 | 아실화 옥신토모듈린 펩타이드 유사체 |
| EP18846196.6A EP3670529B1 (en) | 2017-08-16 | 2018-08-16 | Acylated oxyntomodulin peptide analog |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS65414B1 true RS65414B1 (sr) | 2024-05-31 |
Family
ID=65562699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20240329A RS65414B1 (sr) | 2017-08-16 | 2018-08-16 | Peptidni analog acilovanog oksintomodulina |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11236142B2 (sr) |
| EP (2) | EP3670529B1 (sr) |
| JP (2) | JP7211659B2 (sr) |
| KR (2) | KR102230363B1 (sr) |
| CN (3) | CN117603337A (sr) |
| AU (1) | AU2018318672B2 (sr) |
| BR (1) | BR112020003319A2 (sr) |
| CA (1) | CA3073011C (sr) |
| ES (1) | ES2973986T3 (sr) |
| HR (1) | HRP20240371T1 (sr) |
| HU (1) | HUE065912T2 (sr) |
| IL (1) | IL272606B1 (sr) |
| MX (2) | MX2020001761A (sr) |
| PH (1) | PH12020500338A1 (sr) |
| PL (1) | PL3670529T3 (sr) |
| RS (1) | RS65414B1 (sr) |
| RU (1) | RU2752787C1 (sr) |
| SA (2) | SA520411366B1 (sr) |
| SG (1) | SG11202001283PA (sr) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023521491A (ja) * | 2020-04-20 | 2023-05-24 | ハンミ ファーマシューティカル カンパニー リミテッド | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体又はその結合体を含む高脂血症の予防又は治療用薬学的組成物及び予防又は治療方法 |
| KR102154959B1 (ko) * | 2020-04-29 | 2020-09-10 | 동아에스티 주식회사 | 지속형 glp-1 및 글루카곤 수용체 이중작용제 |
| CN115975057B (zh) * | 2023-03-16 | 2023-05-16 | 杭州信海医药科技有限公司 | 一种可妥度肽的固相合成方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5297817B2 (ja) * | 2006-02-22 | 2013-09-25 | メルク・シャープ・アンド・ドーム・コーポレーション | オキシントモジュリン誘導体 |
| CA2747112A1 (en) * | 2008-12-15 | 2010-06-24 | Zealand Pharma A/S | Glucagon analogues |
| KR101593406B1 (ko) * | 2008-12-15 | 2016-02-12 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| KR20110126591A (ko) * | 2008-12-15 | 2011-11-23 | 질랜드 파마 에이/에스 | 글루카곤 유사체 |
| WO2010096052A1 (en) * | 2009-02-19 | 2010-08-26 | Merck Sharp & Dohme Corp. | Oxyntomodulin analogs |
| AR081975A1 (es) * | 2010-06-23 | 2012-10-31 | Zealand Pharma As | Analogos de glucagon |
| MX2012014961A (es) * | 2010-06-24 | 2013-02-26 | Zealand Pharma As | Analogos de glucagon. |
| CN109306015B (zh) * | 2011-06-17 | 2022-04-26 | 韩美科学株式会社 | 包括泌酸调节肽和免疫球蛋白片段的结合物以及其应用 |
| AU2012357739A1 (en) * | 2011-12-23 | 2014-07-03 | Boehringer Ingelheim International Gmbh | Glucagon analogues |
| BR112014025951A2 (pt) * | 2012-04-19 | 2017-07-11 | Opko Biologics Ltd | variantes de oxintomodulina de longa ação e métodos de produção do mesmo |
| CN109096387B (zh) * | 2012-06-04 | 2021-11-30 | 奥普科生物制品有限公司 | 聚乙二醇化的oxm变体 |
| KR101968344B1 (ko) * | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
| CN105324125A (zh) * | 2013-03-15 | 2016-02-10 | 印第安纳大学研究及科技有限公司 | 具有长效的前体药物 |
| US9988429B2 (en) * | 2013-10-17 | 2018-06-05 | Zealand Pharma A/S | Glucagon analogues |
| CN106519015B (zh) * | 2014-09-23 | 2020-04-17 | 深圳市图微安创科技开发有限公司 | 胃泌酸调节素类似物 |
| EP3206710B1 (en) * | 2014-09-24 | 2020-05-06 | Indiana University Research & Technology Corporation | Incretin-insulin conjugates |
| WO2016090628A1 (zh) * | 2014-12-12 | 2016-06-16 | 北京韩美药品有限公司 | 胃泌酸调节肽(oxm)类似物、其合成及应用 |
| US20190000928A1 (en) * | 2015-06-17 | 2019-01-03 | The California Institute For Biomedical Research | Modified therapeutic agents and compositions thereof |
| US20190175744A1 (en) * | 2016-03-18 | 2019-06-13 | Merck Sharp & Dohme Corp. | Insulin-incretin conjugates |
-
2018
- 2018-08-16 US US16/638,970 patent/US11236142B2/en active Active
- 2018-08-16 SG SG11202001283PA patent/SG11202001283PA/en unknown
- 2018-08-16 PL PL18846196.6T patent/PL3670529T3/pl unknown
- 2018-08-16 KR KR1020180095717A patent/KR102230363B1/ko active IP Right Grant
- 2018-08-16 EP EP18846196.6A patent/EP3670529B1/en active Active
- 2018-08-16 MX MX2020001761A patent/MX2020001761A/es unknown
- 2018-08-16 EP EP22170622.9A patent/EP4079757A1/en active Pending
- 2018-08-16 JP JP2020508489A patent/JP7211659B2/ja active Active
- 2018-08-16 CA CA3073011A patent/CA3073011C/en active Active
- 2018-08-16 RS RS20240329A patent/RS65414B1/sr unknown
- 2018-08-16 AU AU2018318672A patent/AU2018318672B2/en active Active
- 2018-08-16 ES ES18846196T patent/ES2973986T3/es active Active
- 2018-08-16 CN CN202410003809.3A patent/CN117603337A/zh active Pending
- 2018-08-16 RU RU2020108518A patent/RU2752787C1/ru active
- 2018-08-16 HU HUE18846196A patent/HUE065912T2/hu unknown
- 2018-08-16 IL IL272606A patent/IL272606B1/en unknown
- 2018-08-16 CN CN202310958807.5A patent/CN116854804A/zh active Pending
- 2018-08-16 BR BR112020003319-7A patent/BR112020003319A2/pt unknown
- 2018-08-16 CN CN201880053473.4A patent/CN111094331B/zh active Active
- 2018-08-16 HR HRP20240371TT patent/HRP20240371T1/hr unknown
-
2020
- 2020-02-13 MX MX2024000276A patent/MX2024000276A/es unknown
- 2020-02-14 PH PH12020500338A patent/PH12020500338A1/en unknown
- 2020-02-16 SA SA520411366A patent/SA520411366B1/ar unknown
- 2020-02-16 SA SA522432563A patent/SA522432563B1/ar unknown
- 2020-03-31 KR KR1020200039264A patent/KR102230368B1/ko active IP Right Grant
-
2021
- 2021-08-24 US US17/410,697 patent/US11713344B2/en active Active
- 2021-10-27 JP JP2021175902A patent/JP7443315B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275298B1 (en) | Mitochondria-targeted peptides | |
| GB201719557D0 (en) | Polypeptide | |
| HK1254601A1 (zh) | 新型肽 | |
| HK1248729A1 (zh) | 細胞毒性hexim1肽和其用途 | |
| SG11202005653RA (en) | Novel peptide | |
| IL272606A (en) | An acyl-modified peptide oxyntomodulin analog | |
| GB201700557D0 (en) | Novel peptides | |
| IL283553A (en) | Oxyntomodulin analogue peptide preparations | |
| EP3653063A4 (en) | PEPTIDE | |
| EP3480212C0 (en) | IL13RALPHA2 PEPTIDE AND ITS USES | |
| EP3725884A4 (en) | PEPTIDE CAPABLE OF CROSSING THE CELLULAR MEMBRANE | |
| GB201713700D0 (en) | Peptide conjugates | |
| IL284006A (en) | Mitochondria-targeted peptides | |
| GB201612150D0 (en) | Modified peptide | |
| EP3697808C0 (en) | NEUROPROTECTIVE PEPTIDE | |
| IL275278A (en) | Elastomeric peptide | |
| GB201715379D0 (en) | Peptides | |
| GB201715378D0 (en) | Peptides | |
| GB201711620D0 (en) | Peptides | |
| GB201707837D0 (en) | Peptides | |
| GB201717773D0 (en) | Peptide Synthesis | |
| GB201814440D0 (en) | Peptide | |
| GB201807863D0 (en) | Peptides | |
| GB201803074D0 (en) | Peptide | |
| GB201806181D0 (en) | Peptides |